NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 45,000 Shares

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 45,000 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The sale was disclosed in a legal filing with the SEC, which is available through this link.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock traded up $0.69 during trading on Tuesday, reaching $17.29. The company’s stock had a trading volume of 454,562 shares, compared to its average volume of 258,218. The company has a 50-day moving average price of $16.54 and a two-hundred day moving average price of $18.96. NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $2.20 million. As a group, equities analysts forecast that NewAmsterdam Pharma will post -2.06 earnings per share for the current year.

Analyst Ratings Changes

NAMS has been the topic of a number of recent analyst reports. Needham & Company LLC assumed coverage on NewAmsterdam Pharma in a report on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, September 5th. Finally, Piper Sandler reissued an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $33.80.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Parkman Healthcare Partners LLC increased its stake in NewAmsterdam Pharma by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock worth $3,359,000 after purchasing an additional 51,726 shares during the period. TimesSquare Capital Management LLC bought a new position in NewAmsterdam Pharma during the 1st quarter worth about $5,407,000. Opaleye Management Inc. acquired a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at about $2,964,000. Jennison Associates LLC acquired a new position in NewAmsterdam Pharma in the first quarter valued at approximately $22,015,000. Finally, Janus Henderson Group PLC purchased a new stake in NewAmsterdam Pharma during the 1st quarter worth approximately $15,018,000. Institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.